108 related articles for article (PubMed ID: 38835369)
1. Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study.
Mancari R; Yusuf Y; Macuks R; Achimas-Cadariu P; Piek JM; Sperduti I; Corrado G; Vizza E; Zapardiel I
Front Oncol; 2024; 14():1393707. PubMed ID: 38835369
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study.
Macuks R; Yildirim Y; Mancari R; Achimas-Cadariu P; Madhuri TK; Ortega E; Mallmann M; Zivanovic O; Zapardiel I;
Arch Gynecol Obstet; 2023 Sep; 308(3):981-988. PubMed ID: 37193821
[TBL] [Abstract][Full Text] [Related]
3. How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
Rovirosa A; Ascaso C; Ordi J; Arenas M; Valduvieco I; Lejarcegui JA; Pahisa J; Torne A; Biete A
Clin Transl Oncol; 2009 Oct; 11(10):681-7. PubMed ID: 19828411
[TBL] [Abstract][Full Text] [Related]
4. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with uterine sarcoma: the SARCUT study.
Zapardiel I; Gracia Segovia M; Macuks R; Mancari R; Achimas-Cadariu P; Corrado G; Bartusevicius A; Sukhin V; Muruzabal JC; Coronado Martín PJ; Gardella B; Piek JM; Concin N; Arab C; Papatheodorou D; Polterauer S; Iacoponi S; Nieto T; Lopez-Sanclemente MC; Trukhan H; Gil MM; Bakinovskaya I; Dalamanava A; Cucurull M; Rovski D; Baquedano L; Chiva L; Mardas M; Mavrichev SA; Klat J; Lopez de la Manzanara CA; Yildirim Y;
Int J Gynecol Cancer; 2023 Jun; 33(6):897-904. PubMed ID: 37192761
[TBL] [Abstract][Full Text] [Related]
6. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
7. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.
Carroll A; Ramirez PT; Westin SN; Soliman PT; Munsell MF; Nick AM; Schmeler KM; Klopp AH; Fleming ND
Gynecol Oncol; 2014 Dec; 135(3):455-61. PubMed ID: 25449308
[TBL] [Abstract][Full Text] [Related]
8. Uterine Adenosarcoma: A Retrospective 12-Year Single-Center Study.
Yuan Z; Shen K; Yang J; Cao D; Zhang Y; Zhou H; Wu H; Yu M
Front Oncol; 2019; 9():237. PubMed ID: 31139558
[No Abstract] [Full Text] [Related]
9. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
10. Low-Grade Endometrial Stromal Sarcoma and Uterine Adenosarcoma: A Comparison of Clinical Manifestations and Outcomes.
Zhang Y; Li Y; Huang H; Yang J; Wu M; Jin Y; Pan L
J Cancer; 2019; 10(15):3352-3360. PubMed ID: 31293638
[No Abstract] [Full Text] [Related]
11. Uterine and Cervical Adenosarcoma: A Retrospective Study of Overall Oncologic Outcomes and Fertility Preservation in Early-Stage Disease.
Yuan Z; Cao D; Yu M; Shen K; He Y
Oncologist; 2019 Sep; 24(9):e870-e879. PubMed ID: 31127022
[TBL] [Abstract][Full Text] [Related]
12. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
14. Embryonal Rhabdomyosarcoma of the Uterine Cervix: A Clinicopathologic Study of 94 Cases Emphasizing Issues in Differential Diagnosis Staging, and Prognostic Factors.
Devins KM; Young RH; Ghioni M; Burandt E; Bennett JA; Oliva E
Am J Surg Pathol; 2022 Nov; 46(11):1477-1489. PubMed ID: 35941719
[TBL] [Abstract][Full Text] [Related]
15. Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.
Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Polterauer S; Iacoponi S; Zapardiel I;
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900255
[TBL] [Abstract][Full Text] [Related]
16. Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: A case report of aggressive disease in a young patient.
Morales F DA; Medina R ML; Trujillo LM; Beltrán MI; Dulcey IC
Int J Surg Case Rep; 2016; 27():155-161. PubMed ID: 27621097
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma.
Hu H; Wei Z; Zhao H; Yuan G
Medicine (Baltimore); 2022 Sep; 101(38):e30607. PubMed ID: 36197202
[TBL] [Abstract][Full Text] [Related]
18. Uterine carcinosarcoma: A 10-year single institution experience.
Terblanche L; Botha MH
PLoS One; 2022; 17(7):e0271526. PubMed ID: 35862371
[TBL] [Abstract][Full Text] [Related]
19. Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management.
Tate K; Watanabe R; Yoshida H; Shimizu H; Uehara T; Ishikawa M; Ikeda SI; Hiraoka N; Kato T
Asia Pac J Clin Oncol; 2018 Aug; 14(4):318-325. PubMed ID: 29441675
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas.
Gungorduk K; Ozdemir A; Ertas IE; Gokcu M; Telli E; Oge T; Sahbaz A; Sayhan S; Sanci M; Harma M; Ozalp S
Cancer Res Treat; 2015 Apr; 47(2):282-9. PubMed ID: 25358384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
